Anyone who was diagnosed with certain types of  cancer after taking Valsartan may now qualify for a significant cash settlement from the manufacturer. Time to file for compensation is limited! Complete the form below to check eligibility.

In July 2018, the FDA announced a nationwide recall was issued for certain versions of generic valsartan and valsartan HCTZ, after it was discovered that they may be contaminated with an impurity known as N-nitrosodimethylamine (NDMA), which is a known human carcinogen. 

NDMA has been a known human carcinogen since at least 2005. The EPA has set a maximum daily limit of 96 nanograms of NDMA per day. However, recalled valsartan pills may have had levels of NDMA that exceed those safe limits, according to the FDA.

It appears that the manufacturers of generic valsartan failed to conduct adequate testing to ensure that the drugs were safe for consumers, potentially exposing them to a cancer-causing agent for years.

  These lawsuits may result in significant cash settlements for those who have suffered serious complications. To find out if you or a loved one may be eligible for compensation, complete the form on this page for a free case review.

By clicking the button above, I consent to being contacted at the number I provided by Stop Defective Drugs, Stop Defective Products or an attorney, or law firm or it's agents which may include being contacted by an autodialer, text message or pre-recorded call. I acknowledge that standard message and data rates apply and that clicking the button constitutes my electronic signature for my consent to being contacted.

Step 1. 

Complete form on top of this page.

TIME IS LIMITED

Step 2. 

You will be contacted within 

Minutes for a free case review. 

Step 3.

Only way we get compensated is if 

we win your case. NO WIN NO FEE

ATTORNEY ADVERTISING – The information on this website is for general information purposes only. Nothing on this site should be taken as legal advice for any individual case or situation. This information is not intended to create, and receipt or viewing does not constitute, an attorney-client relationship. This website may constitute attorney advertising. Prior results do not guarantee a similar outcome.

Copyright © 2018 STOPDEFECTIVEDRUGS

The FDA approved this medication after it determined that the benefits of the product outweigh the known risks for the intended use. Your doctor prescribed this and/or any other medication to treat an underlying medical condition and stopping the use of any prescribed medication without consulting your physician is dangerous.

DO NOT STOP TAKING THIS MEDICATION OR ANY PRESCRIBED MEDICATION WITHOUT CONSULTING WITH YOUR PHYSICIAN FIRST. 

Submitting this form and the information contained therein does not establish an attorney client relationship. The information submitted may be reviewed by more than one attorney and/or law firm. By submitting this form, you understand any information received in response to this questionnaire is general information for which there will be no charge. You further acknowledge that the law for each state may vary, and therefore, you will not rely upon this information as legal advice. Since this matter may require advice regarding your home state, local counsel may be contacted for referral of this matter. By clicking NEXT, you acknowledge that the information viewed is advertising and you agree to receive future advertisements from Stop Defective Drugs and/or its partners.

Data Use Policy: 

The information you provide while taking this evaluation may be provided to an attorney or law firm representing clients in your area. An attorney or law firm may contact you by phone or text message regarding this matter. Stop Defective Drugs will not provide your contact information to any unaffiliated third parties.

By clicking the button above, I consent to being contacted at the number I provided by Stop Defective Drugs or an attorney, or law firm which may include being contacted by an autodialer, text message or pre-recorded call. I acknowledge that standard message and data rates apply and that clicking NEXT constitutes my electronic signature for my consent to being contacted.